Citigroup: SINO BIOPHARM (01177) Acquisition of siRNA Firm Enhances Out-Licensing Potential; Sets Target Price at HK$10.8, "Buy" Rating

Stock News01-16 09:18

Citigroup released a research report stating that SINO BIOPHARM (01177) announced the acquisition of Hygieia, a private biotech company specializing in small interfering RNA (siRNA) drugs, for a maximum base consideration of 1.2 billion yuan. The bank believes this acquisition further enhances SINO BIOPHARM's innovation capabilities and out-licensing potential, solidifying its position as a leading innovative pharmaceutical company in China. It maintains a target price of HK$10.8 and a "Buy" rating. Hygieia has developed multiple differentiated delivery platforms, and its R&D pipeline includes drug candidates such as Kylo-11, Kylo-12, Kylo-0603, HJY-10, and HJY-02. Through this acquisition, SINO BIOPHARM will establish a next-generation cardiovascular innovation pipeline, strengthen its presence in the weight management and metabolic diseases sector, and expand into new frontiers of the chronic disease management market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment